![tirzepatide surpass-5 Efficacy of in phase 2 (GPGB; [14]) and phase 3 (SURPASS-1 New Dual Incretin Agonist for](https://www.researchgate.net/publication/363201315/figure/fig3/AS:11431281082605778@1662084799021/Efficacy-of-tirzepatide-in-phase-2-GPGB-14-and-phase-3-SURPASS-1-to-5-15-19.png)
tirzepatide surpass-5 Efficacy of in phase 2 (GPGB; [14]) and phase 3 (SURPASS-1 New Dual Incretin Agonist for
Description
Incretin hormones: Their role in health and disease
![tirzepatide surpass-5 Efficacy of in phase 2 (GPGB; [14]) and phase 3 (SURPASS-1 New Dual Incretin Agonist for](https://www.uspharmacist.com/CMSImagesContent/2022/Tirzepatide-T1.gif)
If you see particulates, cloudiness, or discoloration other than pink, do not use the vial
![tirzepatide surpass-5 Efficacy of in phase 2 (GPGB; [14]) and phase 3 (SURPASS-1 New Dual Incretin Agonist for](https://www.researchgate.net/publication/381212710/figure/tbl3/AS:11431281251283441@1718173626979/Results-of-SURPASS-1-5-for-tirzepatide-treatment-in-T2D.png)
The initial dose is typically 2.5 mg, administered once weekly, allowing the body to adjust before increasing the amount
![tirzepatide surpass-5 Efficacy of in phase 2 (GPGB; [14]) and phase 3 (SURPASS-1 New Dual Incretin Agonist for](https://www.nejm.org/cms/asset/67482ba8-0712-42b2-8a78-c184135fcbe8/nejmoa2416394_f1.jpg)
This dual-action mechanism helps lower blood sugar levels and control appetite
![tirzepatide surpass-5 Efficacy of in phase 2 (GPGB; [14]) and phase 3 (SURPASS-1 New Dual Incretin Agonist for](https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fs12933-023-01797-5/MediaObjects/12933_2023_1797_Fig1_HTML.png)
That nuance matters
![tirzepatide surpass-5 Efficacy of in phase 2 (GPGB; [14]) and phase 3 (SURPASS-1 New Dual Incretin Agonist for](https://pbs.twimg.com/media/FAWydfmWEAIHYal.jpg)
Sign up for our 5 Part education series
![tirzepatide surpass-5 Efficacy of in phase 2 (GPGB; [14]) and phase 3 (SURPASS-1 New Dual Incretin Agonist for](https://image.slidesharecdn.com/tirzepatidesedgranadajun2021-210609173001/75/TIRZEPATIDE-COAGONISTA-GIP-GP1-DESARROLLO-CLINICO-SURPASS-5-2048.jpg)
